



# Mektovi in Saudi Arabia

*The SFDA named-patient coordination pathway — indicative 2026*

ONCOLOGY · BRAF-MUTANT MELANOMA

## The clinical situation

Mektovi (binimetinib) is an FDA-approved oral selective MEK1/2 inhibitor dosed 45 mg twice daily in combination with encorafenib for BRAF V600-mutant unresectable or metastatic melanoma, and for BRAF V600E-mutant metastatic NSCLC. Manufactured by Pfizer. Requires documented BRAF V600 mutation testing and coordinated initiation with the BRAF-inhibitor combination partner.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist confirms BRAF V600 mutation status and documents a written clinical rationale and prior line history.
- 2 Treatment facility confirmed.** A Saudi oncology centre (Riyadh, Jeddah, or Eastern Province tertiary facility) accepts the case and sets the combination-therapy plan.
- 3 SFDA named-patient application.** Clinical rationale, patient reference, product details, and chain-of-custody plan are filed with the Saudi Food & Drug Authority.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner, booked to your initiation date.
- 5 Arrival & administration.** The facility receives the product and initiates under your oncologist's care; ongoing cycles dispensed per the combination protocol.

### Indicative economics

**Reference US cash-pay range:** USD 10,000–12,000 per 30-day supply. Combination partner (encorafenib), SFDA documentation, logistics, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-dose timing

**7–14 days** from a complete SFDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review. **Logistics.** Temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Mektovi × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/mektovi-saudi-arabia.html](https://reservemed.com/access-guides/mektovi-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team